NSE: AUROPHARMA · 1 October 2026 · Dated market coverage
Previous close
₹1,697.70
High / Low
₹1,713.70 / ₹1,690.70
Volume
1,159,038
Previous trading day
29 September 2026
Pre-Market News Brief:01 Oct 2026 • 09:04 AM IST Market status:Cash market not yet open
AUROPHARMA • NSE • F&O Stock
AUROBINDO PHARMA LTD
In focus: Acrotech Biopharma Launches ADQUEY in the U.S. and Establishes Dermatology Business
Aurobindo Pharma is in focus after its subsidiary, Acrotech Biopharma, announced the U.S. launch of ADQUEY and the establishment of a dedicated dermatology business. The development highlights ongoing commercial expansion in key international markets heading into the trading session.
Why AUROBINDO PHARMA LTD Is in Focus Before Market Open
- Subsidiary expansion into the U.S. dermatology sector broadens Acrotech Biopharma’s commercial footprint.
- Product launches in regulated markets like the U.S. serve as key growth drivers for the pharmaceutical portfolio.
- Official exchange filings confirm the strategic update ahead of the market open.
Completed-session market data shown above refers to 2026-09-29; no pre-open price reaction is assumed.
Latest Company News and Disclosures
Press Release
NSE • 30-Sep-2026 21:24:08
a press release dated September 30, 2026, titled “Acrotech Biopharma Launches ADQUEY in the U.S. and Establishes Dedicated Dermatology Business”.
What to Watch After the Market Opens
- Market reaction and trading volume relative to the 20-day average volume of 1,159,038 shares.
- Price action around the previous close of Rs. 1,697.70 and the recent 20-day high of Rs. 1,740.00.
- Intraday sentiment regarding the commercial potential of the new dermatology business.
Article by WittyTrades Research Desk
Disclaimer:Investments in securities markets are subject to market risks. This pre-market article is informational and does not predict the opening direction or constitute a recommendation.
Other Dated Coverage
More Aurobindo Pharma news and dated analysis →
Article by: WittyTrades Research Desk